Phase III CBD Heart Disease Trial Expands After Blinded Review Finds Fewer Pericarditis Recurrences Than Expected

Phase III CBD Heart Disease Trial Expands After Blinded Review Finds Fewer Pericarditis Recurrences Than Expected

The Marijuana Herald - Marijuana news and information A Phase III clinical trial testing a cannabidiol (CBD) formulation for recurrent pericarditis is being expanded after a blinded review found fewer disease recurrences than … Continue reading

Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™’s Efficacy

Original 110-patient enrollment target achieved ahead of the Company’s end-of-September guidance. The MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to capture sufficient events for a robust assessment of CardiolRx™’s potential to reduce recurrence risk. The recommendation follows a blinded review showing fewer-than-expected recurrences—an observation the Company views as encouraging.